PHASQ Stock Crashes 99% on May 9, 2026 After Bankruptcy

PHASQ stock has become one of the market’s most severe casualties, trading at just $0.000001 USD on the PNK exchange as of May 9, 2026. The biotech company PhaseBio Pharmaceuticals, Inc. has experienced a devastating 99% decline, reflecting the aftermath of its October 2022 Chapter 11 bankruptcy filing. Once a clinical-stage biopharmaceutical firm focused on cardiovascular treatments, PHASQ stock now trades with minimal volume and virtually no market capitalization. The company’s lead candidate bentracimab (PB2452) and pipeline programs have failed to generate investor confidence. This collapse represents a cautionary tale for biotech investors betting on clinical-stage drug development.

PHASQ Stock Price Collapse and Trading Activity

PHASQ stock trades at an almost worthless $0.000001 per share, down from $0.0001 the previous close. The stock has lost 99% of its value over the past year, with volume dropping to just 2,500 shares traded against an average of 22,310 shares. The year-to-date performance shows consistent deterioration, with the stock hitting a 52-week low matching its current price. Track PHASQ on Meyka for real-time updates on this distressed security.

Historical Price Deterioration

The 52-week high of $0.0399 reveals how far PHASQ stock has fallen in just months. The 50-day moving average sits at $0.000236, while the 200-day average is $0.000666, both indicating sustained downward pressure. These technical levels show no recovery momentum. The stock’s inability to hold any price floor signals complete loss of investor interest and fundamental value destruction.

Financial Metrics Show Severe Distress

PhaseBio’s financial position reflects a company in terminal decline. The company reports negative earnings per share of -$2.14, with a price-to-earnings ratio that’s essentially meaningless at this valuation. Market capitalization has collapsed to zero, indicating the stock trades on bankruptcy proceedings rather than business fundamentals. The enterprise value sits at negative $33.48 million, reflecting liabilities exceeding any remaining assets.

Profitability and Cash Flow Crisis

Operating margins are deeply negative at -9.91%, while net profit margins stand at -12.10%. Free cash flow per share is negative $1.14, showing the company burns cash without generating revenue. The company’s operating cash flow is also negative at -$1.08 per share. These metrics confirm PhaseBio cannot sustain operations or fund drug development independently.

Bankruptcy Impact and Pipeline Status

PhaseBio Pharmaceuticals filed for Chapter 11 reorganization on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware. This filing marked the end of the company’s independent operations and triggered the stock’s catastrophic decline. The bankruptcy process has essentially wiped out equity holders, leaving PHASQ stock as a penny stock with minimal recovery prospects.

Clinical Programs and Asset Status

The company’s lead candidate bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor, remains in Phase III trials but lacks funding for completion. Secondary programs including PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension have stalled. The co-development agreement with SFJ Pharmaceuticals X, Ltd. provides limited support. With only 60 full-time employees remaining, the company cannot advance its pipeline or commercialize any products.

Market Sentiment and Trading Dynamics

PHASQ stock trades with virtually no institutional interest or analyst coverage. The stock’s penny status on the PNK exchange limits accessibility for most retail investors. Relative volume is just 11.2% of average, indicating minimal daily trading activity and extreme illiquidity.

Trading Activity and Liquidation Pressure

The collapse in trading volume reflects forced liquidation by bankruptcy trustees and complete abandonment by investors. Bid-ask spreads are likely extremely wide, making any exit nearly impossible at quoted prices. The stock’s status as a bankruptcy play means future value depends entirely on asset recovery and creditor settlements, not business operations. Most shareholders have already written off their positions as total losses.

Final Thoughts

PHASQ stock has collapsed to $0.000001 following PhaseBio’s 2022 bankruptcy, with no funding or development momentum for its clinical pipeline. The company shows negative profitability, zero market value, and no intrinsic worth. Recovery is unlikely without major asset acquisition or creditor restructuring. This illustrates extreme biotech investment risks when clinical programs stall and funding disappears.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.